Article
Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP…
medRxiv · 2018 · Jonathan P Mochel
Key facts
| Title | Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation |
|---|---|
| First author | Jonathan P Mochel |
| Journal | medRxiv |
| Published | Oct 5, 2018 |
| DOI | 10.1101/435560 |
| Devices mentioned | K031359 |
| Product codes mentioned | JKA, PQD, PJE |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1